All In Biotech

Drug Trial Radar · NCT07059767

Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge

A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jun 24, 2025

Primary completion

Sep 1, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Ethris GmbHIndustry
Sponsor type
Industry
Collaborators
VirTus Respiratory Research Ltd
First posted
Jul 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge

Conditions

  • Asthma (Diagnosis)

Interventions

  • ETH47Drug

    single intranasal dose of ETH47

  • PlaceboDrug

    single intranasal dose of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in peak of total lower respiratory symptoms score (LRSS)Time frame: Day 1 to Day 14

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Medicines Evaluation Unit Limited

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.